Italy’s Angelini Sues Actavis Over Generic Oleptro

Aziende Chimiche Riunite Angelini Francesco Acraf SpA sued an affiliate of Icelandic generic drugmaker Actavis Group HF for infringing a patent for the antidepressant Oleptro.

Actavis South Atlantic LLC, based in Sunrise, Florida, plans to sell copies of the drug before the patent expires, Rome-based Angelini said in a complaint filed today in federal court in Wilmington, Delaware.

“Plaintiffs will be irreparably harmed by defendant’s infringing activities” unless stopped by the court, according to the complaint.

The Italian company asked for a permanent injunction against Actavis’s sale of copies of the drug until patent protection ends in 2029.

David Myers Jr., a U.S. spokesman for Actavis, didn’t immediately return voice-mail and e-mail messages seeking comment on the lawsuit.

The case is Aziende Chimiche v. Actavis, U.S. District Court, District of Delaware (Wilmington.)

To see the patent, click: 8,133,893.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware at pmilford@bloomberg.net

To contact the editor responsible for this story: Andrew Dunn at adunn8@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.